Therapy May Not Benefit MAT Care in Early Recovery, Study Suggests

A new randomized clinical trial suggests that adding cognitive-behavioral therapy or peer recovery support to buprenorphine treatment may not add measurable benefit in the earliest weeks of care, though the study’s authors are careful to note this finding applies to their specific trial population and timing, not to the value of counseling and peer support in addiction treatment generally.

The study, published June 23, 2026 in JAMA Network Open, followed 340 adults with opioid use disorder at five federally qualified health centers who had recently started office-based buprenorphine treatment.

What Researchers Tested

Participants were randomly assigned to one of four groups: standard buprenorphine care alone, buprenorphine plus 12 weeks of cognitive-behavioral therapy (CBT), buprenorphine plus 12 weeks of peer recovery support (PRS), or buprenorphine with both interventions combined.

Buprenorphine is a medication used in medication-assisted treatment for opioid use disorder, and clinical guidelines generally recommend assessing patients for psychosocial support needs alongside medication.

Researchers tracked urine drug screening results over a full year to measure opioid abstinence, along with treatment retention, quality of life, and emergency department use.

The Results Were Largely Null, With Caveats

In this trial, neither CBT nor peer recovery support, alone or combined, was associated with a statistically significant reduction in opioid-positive drug screens compared with buprenorphine alone during the first year of treatment.

Treatment retention also did not differ meaningfully by group. The authors were explicit that this does not mean counseling or peer support lack value broadly, only that adding them at this particular stage did not produce a measurable difference in this study.

A major factor the researchers highlighted was limited engagement: participants received a median of just three or four sessions out of the twelve offered in each psychosocial track.

Barriers such as transportation, stigma around medication-assisted treatment, and general life instability in early recovery likely limited how much of each intervention participants actually received, which the authors said may explain much of the null result.

Understanding Medication-Assisted Treatment

Medication-assisted treatment combines FDA-approved medications, such as buprenorphine, methadone, or naltrexone, with counseling and support services to treat opioid use disorder.

Buprenorphine itself reduces withdrawal symptoms and cravings by acting on the same brain receptors as opioids, without producing the same intensity of effect, and is considered a first-line treatment for opioid use disorder on its own.

The study’s authors noted their findings echo several earlier studies that also found limited added benefit from CBT layered on top of buprenorphine specifically in early treatment, while stressing that psychosocial support may still matter more once someone is further along in recovery.

What This Means for Patients and Providers

The findings do not suggest that counseling or peer support should be removed from addiction treatment. Instead, the study’s authors proposed that psychosocial support might be more effective once someone is more stable in recovery, rather than introduced at the very start of medication-assisted treatment, and called for further research into telehealth delivery and longer-duration support to improve engagement rates.

Finding Medical Detox and Treatment Support

Never attempt to stop opioids or begin a new medication regimen without medical supervision, since withdrawal can carry serious health risks.

If you are exploring medically supervised detox or medication-assisted treatment options, detox.com’s directory lists detox programs that combine buprenorphine, methadone, or naltrexone with support tailored to your stage of recovery. Call 800-996-6135(Sponsored) for free, confidential guidance in finding medically supervised programs near you.